AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

November 5, 2019 GMT

BEDFORD, Mass.--(BUSINESS WIRE)--Nov 5, 2019--

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two investor conferences in November:

Credit Suisse 28th Annual Healthcare Conference
Date:
Tuesday, November 12, 2019
Time: 4:10 p.m. MT
Location: Scottsdale, AZ

Stifel 2019 Healthcare Conference
Date:
Wednesday, November 20, 2019
Time: 4:10 p.m. ET
Location: New York, NY

A live audio webcast of the presentations will be available on the Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcasts will be available for 30 days following the presentations.

About Stoke Therapeutics

Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The company’s lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191105005067/en/

CONTACT: Stoke Media & Investor Contact:

Dawn Kalmar

Vice President, Head of Corporate Affairs

dkalmar@stoketherapeutics.com

781-303-8302

KEYWORD: MASSACHUSETTS NEW YORK ARIZONA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH GENETICS OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Stoke Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/05/2019 08:30 AM/DISC: 11/05/2019 08:30 AM

http://www.businesswire.com/news/home/20191105005067/en